We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
- Authors
Kong, Xiang-Yun; Lu, Jian-Xun; Yu, Xin-Wen; Zhang, Jian; Xu, Qian-Lan; Zhang, Rong-Jun; Mi, Jing-Lin; Liao, Shu-Fang; Fan, Jin-Fang; Qin, Xiao-Li; Yao, Da-Cheng; Tang, Hua-Ying; Jiang, Wei
- Abstract
<bold>Background: </bold>The objective of this study was to evaluate the efficacy and safety of gemcitabine plus cisplatin concurrent chemoradiotherapy (CCRT) in patients with nasopharyngeal carcinoma.<bold>Method: </bold>Patients with NPC were randomly assigned to the gemcitabine plus cisplatin (GP) group or fluorouracil plus cisplatin (PF) group. Primary end-point was disease-free survival (DFS); secondary endpoints: overall survival, distant metastasis-free survival (DMFS), locoregional relapse-free survival, and treatment-related adverse events.<bold>Results: </bold>Seventy-six patients were prospectively enrolled and the median follow-up time was 41 months (9-61 months). Three-year DFS were similar between the GP and PF groups (73.7% vs. 60.5%, HR 0.66, 95% CI 0.30-1.44; P = 0.30). Distant metastasis was the most common failure form in PF compared with GP (P = 0.034). Three-year DMFS was significantly better in the GP group than PF group (89.5% vs. 71.1%, P = 0.045). Grade 3-4 gastrointestinal toxicities (vomiting and diarrhea) were significantly more common in the PF group; grade 3-4 neutropenia and thrombocytopenia were more common in the GP group.<bold>Conclusion: </bold>Gemcitabine plus cisplatin could be used as an alternative regimen in CCRT for nasopharyngeal carcinoma.
- Subjects
ANTIMETABOLITES; CISPLATIN; BUSULFAN; CANCER chemotherapy; CARCINOMA; PROGRESSION-free survival; CHEMORADIOTHERAPY; ADVERSE health care events
- Publication
Cancer Chemotherapy & Pharmacology, 2019, Vol 84, Issue 1, p155
- ISSN
0344-5704
- Publication type
journal article
- DOI
10.1007/s00280-019-03858-7